P. McConville & N. Ayers
Pre-clinical imaging is playing an increasingly important role in the evaluation of new drug candidates’ therapeutic potential. With pre-clinical imaging, researchers can:
- Evaluate drug candidates using more clinically relevant and predictive disease models
- Track disease progression
- Increase decision-making confidence
Quantify endpoints that are directly translatable to clinical
Drug discovery and development scientists can employ a wide array of imaging technologies, including MRI, micro- CT, micro-PET, SPECT, X-Ray and optical (two-dimensional and fluorescence molecular tomography) to quantitatively assess test agent performance at anatomical, functional and molecular levels. Molecular imaging technologies can also be utilized to conduct applications research to develop and optimize the use of imaging, to further advance imaging in the field of drug discovery.
V. Kaimal & P. McConville
J. Chunta & P. McConville
Positron emission tomography (PET) imaging of metabolism with the glucose analog 2-deoxy-2-(18F)fluoro-D-glucose (FDG) has become pivotal in medical research, including oncology and inflammation disease areas, since it uniquely enables a direct measure of glucose utilization. FDG PET has transformed clinical oncology and patient management, and has also become an integral part of drug development.